JP2019529533A - 皮膚ケアおよび/または創傷治癒促進におけるポリ抽出物およびその有効成分の使用 - Google Patents
皮膚ケアおよび/または創傷治癒促進におけるポリ抽出物およびその有効成分の使用 Download PDFInfo
- Publication number
- JP2019529533A JP2019529533A JP2019533271A JP2019533271A JP2019529533A JP 2019529533 A JP2019529533 A JP 2019529533A JP 2019533271 A JP2019533271 A JP 2019533271A JP 2019533271 A JP2019533271 A JP 2019533271A JP 2019529533 A JP2019529533 A JP 2019529533A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- skin
- extract
- pine
- polycoic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 60
- 239000004480 active ingredient Substances 0.000 title claims description 35
- 230000029663 wound healing Effects 0.000 title claims description 30
- 230000001737 promoting effect Effects 0.000 title claims description 15
- 239000002253 acid Substances 0.000 claims abstract description 177
- RWIALJIVPUCERT-DRCQUEPLSA-N (2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3-acetyloxy-16-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound CC1(C)[C@@H](OC(C)=O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)[C@H](O)C[C@@]4(C)C3=CC[C@H]21 RWIALJIVPUCERT-DRCQUEPLSA-N 0.000 claims abstract description 24
- RWIALJIVPUCERT-UHFFFAOYSA-N 3-Ac-(3bata,16alpha)-3,16-Dihydroxy-24-methylenelanosta-7,9(11)-dien-21-oic acid Natural products CC1(C)C(OC(C)=O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC4(C)C3=CCC21 RWIALJIVPUCERT-UHFFFAOYSA-N 0.000 claims abstract description 24
- RWIALJIVPUCERT-DRCQUEPLSA-M 3-Epidehydropachymic Acid Natural products O=C([O-])[C@H](CCC(C(C)C)=C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC=C1[C@]3(C)[C@H](C(C)(C)[C@@H](OC(=O)C)CC3)CC=C21 RWIALJIVPUCERT-DRCQUEPLSA-M 0.000 claims abstract description 24
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 claims abstract description 23
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 claims abstract description 23
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 70
- 241000018646 Pinus brutia Species 0.000 claims description 70
- 235000011613 Pinus brutia Nutrition 0.000 claims description 70
- 102000008186 Collagen Human genes 0.000 claims description 58
- 108010035532 Collagen Proteins 0.000 claims description 58
- 229920001436 collagen Polymers 0.000 claims description 58
- 210000003491 skin Anatomy 0.000 claims description 54
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 45
- 229920002674 hyaluronan Polymers 0.000 claims description 45
- 229960003160 hyaluronic acid Drugs 0.000 claims description 45
- 238000002360 preparation method Methods 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 26
- 210000002615 epidermis Anatomy 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 230000009759 skin aging Effects 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000037303 wrinkles Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000009499 grossing Methods 0.000 claims description 5
- 230000003020 moisturizing effect Effects 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 239000000054 fungal extract Substances 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000037339 smooth wrinkles Effects 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 239000002798 polar solvent Substances 0.000 description 25
- 210000002950 fibroblast Anatomy 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 18
- 239000001963 growth medium Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 239000000287 crude extract Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 244000197580 Poria cocos Species 0.000 description 7
- 235000008599 Poria cocos Nutrition 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 235000013372 meat Nutrition 0.000 description 6
- 229940093611 fu ling Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000000474 Poliomyelitis Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- -1 absorption retardant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000003752 hydrotrope Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ONFPYGOMAADWAT-OXUZYLMNSA-N Dehydroeburicoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)CC[C@@]4(C)C3=CC[C@H]21 ONFPYGOMAADWAT-OXUZYLMNSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 244000057845 Pinus roxburghii Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- QFPLAAZRZNKRRY-UHFFFAOYSA-N dehydrotrametenolic acid Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC=C(C)C)C(O)=O)CCC4(C)C3=CCC21 QFPLAAZRZNKRRY-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
ヒアルロン酸は真皮に豊富に存在する。ヒアルロン酸はムコ多糖類であり、効果的な保湿剤であるため、肌の弾力性や水分量を維持し、しわを減らし、肌の老化を防ぐことができる。
8:1の松塊。
[作成例]
A. 松塊抽出物の調製
皮を剥いて(以下「松塊表皮」という)、残りは肉(以下 「松塊 meat」 という)。
A―2およびA―3の抽出を繰り返し、松塊抽出物を得た。その後、得られた抽出物の成分をA―4の分析法により測定した。その結果,松塊抽出物はデヒドロパキミ酸,パキミ酸,デヒドロツムロース酸,ツムロース酸,ポリポレン酸C,3‐エピ‐デヒドロツムロース酸,デヒドロトラメテノール酸,トラメノール酸,デヒドロエブリコ酸,エブリコ酸,ポリコ酸A,ポリコ酸Bなどを含むことが分かった。
B-1. A―5から得られた松塊抽出物をメタノール(松塊エキス:メタノール=1:500容量)に均一に分散させて混合物を得た。その後、ろ過して不溶物を除去した。残りの濾液を、それぞれ、243nmおよび210nmの波長の分取高速液体クロマトグラフィー(メタノール/水混液の移動相)によって精製し、デヒドロパキミ酸、デヒドロツムロース酸、ツムロース酸、ポリポレン酸C、3-エピ-デヒドロツムロース酸、デヒドロトラメテノール酸、トラメノール酸、デヒドロエブリコ酸、エブリコ酸、ポリコ酸Aおよびポリコ酸Bの一部を回収した。回収した部分を真空濃縮してメタノールを除去し、それぞれデヒドロパキミ酸、パキミ酸、デヒドロツムロース酸、ツムロース酸、ポリポレン酸C、3―エピーデヒドロツムロース酸、デヒドロトラメチノール酸、デヒドロエブリコ酸、エブリコ酸、ポリコ酸Aおよびポリコ酸Bを得た。
正常初代ヒト皮膚線維芽細胞(ATCCから購入)を線維芽細胞増殖培地で培養した。このようにして得られた細胞を以下の実験に用いた。
[調製例C]から提供された正常ヒト初代皮膚線維芽細胞を4グループに分け、それぞれ以下の培地で48時間培養した。
1. グループI:線維芽細胞増殖培地;
2. グループII:[調製例A―3]から得た松塊表皮抽出物0.005μg/mlを含む線維芽細胞増殖培地。;
3. グループIII:[調製例A―3]から得た松塊表皮抽出物0.05μg/mlを含む線維芽細胞増殖培地。;
4. グループIV:[調製例A―3]から得た松塊表皮抽出物0.5μg/mlを含む線維芽細胞増殖培地。
(2-1)コラーゲンの細胞内発現
[調製例C]から提供された正常ヒト初代皮膚線維芽細胞を37群に分け、それぞれ以下の培地で48時間培養した。
1. グループ1:線維芽細胞増殖培地
2. グループ2―1〜グループ2―3:[調製例B]から得られるパキム酸(PA)をそれぞれ0.01μM、0.1μMおよび1μMの濃度で含む線維芽細胞増殖培地;
3. グループ3―1〜グループ3―3:[調製例B]から得られるデヒドロパキミ酸(DPA)を、それぞれ0.01μM、0.1μMおよび1μMの濃度で含む線維芽細胞増殖培地;
4. グループ4―1〜グループ4―3:[調製例B]から得られるツムロース酸(TA)を、それぞれ0.01μM、0.1μMおよび1μMの濃度で含有する線維芽細胞増殖培地;
5. グループ5―1〜グループ5―3:[調製例B]から得られるデヒドロツムロース酸(DTA)をそれぞれ0.01μM、0.1μMおよび1μMの濃度で含む線維芽細胞増殖培地;
6. グループ6―1〜グループ6―3:それぞれ0.01、0.1および1μMの濃度で[調製例B]によって提供されるポリポレン酸C(PAC)を含有する線維芽細胞増殖培地;
7. グループ7―1〜グループ7―3:3―エピーデヒドロツムロース酸(EDTA)を含有する線維芽細胞増殖培地であって、[調製例B]により、それぞれ0.01、0.1および1μMの濃度で提供されるもの;
8. グループ8―1〜グループ8―3:それぞれ0.01μM、0.1μMおよび1μMの濃度の[調製例B]によって提供されるデヒドロトラメテノール酸(DTA)を含有する線維芽細胞増殖培地;
9. グループ9―1〜グループ9―3:それぞれ0.01、0.1および1μMの濃度で[調製例B]によって提供されるトラメノール酸(TTA)を含有する線維芽細胞増殖培地;
10. グループ10―1〜グループ10―3:[調製例B]から得たポリコ酸A(PAA)をそれぞれ0.01μM、0.1μMおよび1μMの濃度で含む線維芽細胞増殖培地;
11. グループ11―1〜11―3:[調製例B]により提供されるデヒドロエブリコ酸(DEA)をそれぞれ0.01、0.1および1μMの濃度で含む線維芽細胞増殖培地;
12. グループ12―1〜グループ12―3:それぞれ0.01、0.1および1μMの濃度で[調製例B]によって提供されたポリ酸B(パブ)を含有する線維芽細胞増殖培地;
13. グループ13―1〜13グループ:[調製例B]から得たエブリコ酸(EA)を、それぞれ
0.01μM、0.1μMおよび1μMの濃度で含む線維芽細胞増殖培地。
コラーゲンの細胞外発現に対する本発明の活性成分の効果を理解するために、実施例(2-1)によって提供された各群の濃縮細胞培地を測定し、ウェスタンブロットおよび酵素結合免疫吸着検定法(ELISA法)によって分析した。各群の培地中のコラーゲン含量(すなわち、コラーゲンの細胞外含量)を測定した。最後に,対照群(すなわち、グループ1の培地で培養されている細胞)の結果を100%とし,他の群のコラーゲンの相対含量(パーセントで表示)を計算する基礎として用いた。その結果を表4に示す。
ヒアルロン酸の細胞外発現に対する本発明の活性成分の効果を理解するために、実施例(21)によって提供された各群の濃縮細胞培地を、ウェスタンブロットおよび酵素結合免疫吸着検定法(ELISA法)によって測定し、分析した。各群の培地中のヒアルロン酸含量(すなわちヒアルロン酸の細胞外含量)を測定した。最後に,対照群(すなわち、グループ1の培地で培養されている細胞)の結果を100%として,他の群のヒアルロン酸の相対含量(パーセントで表示)を計算するための基礎として用いた。その結果を表5に示す。
Claims (14)
- 皮膚の保護および/または創傷治癒の促進のために使用される製剤の製造における松塊抽出物の使用。
- 前記松塊抽出物が、デヒドロパキミ酸(DPA)、パキム酸(PA)、デヒドロツムロース酸(DTA)、ツムロース酸(TA)、ポリポレン酸C(PAC)、3-エピ-デヒドロツムロース酸(EDTA)、デヒドロトラメチノール酸(DTTA)、トラメチノール酸(TTA)、デヒドロエブリコ酸(DEA)、エブリコ酸(EA)、ポリコ酸A(PAA)及びポリコ酸B(PAB)の少なくとも一つを含む、請求項1に記載の使用。
- 前記松塊抽出物が松塊表皮抽出物である、請求項1に記載の使用。
- 前記松塊表皮抽出物において、松塊表皮抽出物の総重量を基準として、ポリコ酸A及びポリコ酸Bの総量が少なくとも40重量%である、請求項3に記載の使用。
- 前記調製物が化粧品、ケア製品または食品として提供され、前記化粧品、ケア製品および食品がコラーゲンおよび/またはヒアルロン酸の発現を増強し、それによって皮膚を保護することができる、請求項1乃至4のいずれか一項に記載の使用。
- 前記化粧品、ケア製品及び食品は、肌に栄養を与えること、肌を引き締めること、肌を補修すること、保湿すること、しわを滑らかにすること、肌の老化を遅らせること、及び肌の老化を防ぐことのうちの少なくとも1つに使用されることを特徴とする請求項5に記載の使用。
- 前記製剤が薬剤として提供され、該薬剤がコラーゲンおよび/またはヒアルロン酸の発現を増強し、それによって創傷治癒を促進する、請求項1乃至4のいずれか一項に記載の使用。
- 皮膚保護及び/又は創傷治癒促進のために用いられる製剤であって、有効成分がデヒドロパキミ酸、パキミ酸、デヒドロツムロース酸、ツムロース酸、ポリポレン酸C、3-エピ-デヒドロツムロース酸、デヒドロトラメチノール酸、トラメチノール酸、デヒドロエブリコ酸、エブリコ酸B、ポリコ酸A及びポリコ酸の少なくとも1つである製剤の製造における有効成分の使用。
- 前記有効成分が、ポリコ酸A及び/又はポリコ酸Bであることを特徴とする請求項8に記載の使用方法。
- 活性成分が抽出物の形態で提供される、請求項8に記載の使用。
- 活性成分が、真菌エキスまたは植物エキスの形態で提供される、請求項10に記載の使用。
- 前記調製物が化粧品、ケア製品または食品として提供され、前記化粧品、ケア製品および食品がコラーゲンおよび/またはヒアルロン酸の発現を増強し、それによって皮膚を保護することができる、請求項8ないし11のいずれか一項に記載の使用。
- 化粧品、ケア製品および食品が、栄養のある皮膚、皮膚の引き締め、皮膚の修復、保湿、しわの平滑化、皮膚老化の遅延、および皮膚老化の予防のうちの少なくとも一つに使用される、請求項12に記載の使用。
- 前記製剤が薬剤として提供され、該薬剤がコラーゲンおよび/またはヒアルロン酸の発現を増強し、それによって創傷治癒を促進する、請求項8ないし11のいずれか一項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662383860P | 2016-09-06 | 2016-09-06 | |
US62/383,860 | 2016-09-06 | ||
PCT/CN2017/100526 WO2018045943A1 (zh) | 2016-09-06 | 2017-09-05 | 茯苓萃取物及其活性成分于保养肌肤及/或促进伤口愈合的用途 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019529533A true JP2019529533A (ja) | 2019-10-17 |
JP2019529533A5 JP2019529533A5 (ja) | 2020-08-13 |
JP6798030B2 JP6798030B2 (ja) | 2020-12-09 |
Family
ID=61281841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019533271A Active JP6798030B2 (ja) | 2016-09-06 | 2017-09-05 | 皮膚ケアおよび/または創傷治癒促進における松塊抽出物およびその有効成分の使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11654169B2 (ja) |
JP (1) | JP6798030B2 (ja) |
KR (1) | KR102295786B1 (ja) |
CN (1) | CN107789373A (ja) |
MY (1) | MY195806A (ja) |
TW (1) | TWI640317B (ja) |
WO (1) | WO2018045943A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102611023B1 (ko) * | 2018-11-21 | 2023-12-08 | (주)아모레퍼시픽 | 탈수소 아비에틱산을 포함하는 피부 장벽 강화용 또는 보습용 피부 외용제 조성물 |
CN111632056B (zh) * | 2020-06-04 | 2023-05-16 | 广东省农业科学院动物卫生研究所 | 松苓新酸及其衍生物在制备抗柔嫩艾美耳球虫的药物中的应用 |
CN114631604A (zh) * | 2020-11-30 | 2022-06-17 | 百岳特生物技术(上海)有限公司 | 植物发酵液改善睡眠质量及/或抗老化的用途 |
TWI784357B (zh) * | 2020-11-30 | 2022-11-21 | 大江生醫股份有限公司 | 植物發酵液改善睡眠品質及/或抗老化的用途 |
CN114146019B (zh) * | 2021-12-29 | 2023-04-18 | 上海应用技术大学 | 一种茯苓多糖提取物及其在抗紫外线中的应用 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08119864A (ja) * | 1994-09-02 | 1996-05-14 | Kotarou Kanpo Seiyaku Kk | 鎮吐薬 |
JPH0925232A (ja) * | 1995-07-14 | 1997-01-28 | Kotarou Kanpo Seiyaku Kk | 発癌予防剤 |
JPH0940552A (ja) * | 1995-08-02 | 1997-02-10 | Kanebo Ltd | ヒトコラゲナーゼ活性阻害剤 |
JPH10237093A (ja) * | 1997-02-28 | 1998-09-08 | Kotarou Kanpo Seiyaku Kk | マツホド抽出成分を含む抗炎症剤 |
JPH10330266A (ja) * | 1997-06-02 | 1998-12-15 | Kotarou Kanpo Seiyaku Kk | インスリン作用増強活性組成物 |
JP2003104905A (ja) * | 2001-09-28 | 2003-04-09 | Nagatomo Yakuhin:Kk | 茸有効成分の抽出方法 |
JP2008105972A (ja) * | 2006-10-24 | 2008-05-08 | Nagatomo Yakuhin:Kk | 生薬の抗腫瘍性有効物質の抽出法 |
JP2011256136A (ja) * | 2010-06-09 | 2011-12-22 | Nihon Univ | コラーゲン分解阻害剤 |
US8168197B2 (en) * | 2007-02-28 | 2012-05-01 | Amorepacific Corporation | External composition for skin containing Scrophularia buergeriana miq. extract and the use thereof for the skin moisturizing cosmetics |
CN103550265A (zh) * | 2013-11-08 | 2014-02-05 | 山东省中医药研究院 | 一种茯苓皮有效成分的提取方法及其提取物 |
KR20160003910A (ko) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | 한약재 추출물을 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2708466B1 (fr) * | 1993-06-30 | 1995-10-27 | Lvmh Rech | Utilisation d'un extrait de champignons Poria cocos Wolf pour la préparation d'une composition cosmétique ou pharmaceutique, notamment dermatologique pour le traitement de l'acné ou des peaux grasses. |
EP1432399A1 (en) | 2001-10-04 | 2004-06-30 | Unilever Plc | Enhancing epidermal barrier development in skin |
DE10151649A1 (de) | 2001-10-11 | 2003-05-08 | Peter Elsner | Verwendung von Lanostanen als Inhibitoren von 3alpha-Hydroxysteroid-Dehydrogenase und Cyclooxygenasen |
US7992280B2 (en) * | 2008-01-07 | 2011-08-09 | Mssc Us | Method of casting metal anti-shift collars for stabilizer bar |
TWI441640B (zh) * | 2008-03-31 | 2014-06-21 | Sinphar Pharmaceutical Co Ltd | 促進營養素被吸收的醫藥組合物及茯苓萃取物 |
TWI367099B (en) * | 2008-06-20 | 2012-07-01 | Sinphar Pharmaceutial Co Ltd | Pharmaceutical composition and extract of poria for treating a disease induced from immune disorder |
US20100233301A1 (en) * | 2009-03-11 | 2010-09-16 | Jing Cheng | Topical compositions comprising fermented extracts of traditional chinese medicinal (tcm) ingredients, and methods of making and using same |
CN101874807B (zh) * | 2009-05-02 | 2013-04-10 | 杏辉天力(杭州)药业有限公司 | 以羊毛固醇及茯苓萃取物治疗恶病质的用途 |
WO2011127994A1 (de) * | 2010-04-12 | 2011-10-20 | Chemisches Laboratorium Dr. Kurt Richter Gmbh | Wirkstoffkomplex und formulierung umfassend denselben |
NZ717728A (en) | 2011-06-17 | 2016-04-29 | Halozyme Inc | Stable formulations of a hyaluronan-degrading enzyme |
TWI513475B (zh) * | 2012-08-31 | 2015-12-21 | Uni President Biotech Co Ltd | 具有亮白、保濕、撫平細紋、緊緻肌膚及調理柔膚功能的紅景天組合物 |
KR102201192B1 (ko) * | 2013-11-18 | 2021-01-12 | 주식회사 엘지생활건강 | 피부 재생, 주름 개선, 항염증 또는 피부 미백용 조성물 |
TWI547284B (zh) * | 2014-05-21 | 2016-09-01 | 杏輝藥品工業股份有限公司 | 茯苓萃取物及其製備方法與應用 |
KR20160057196A (ko) | 2014-11-13 | 2016-05-23 | 주식회사심비오즈코스메틱스 | Pachymic acid를 유효성분으로 함유하는 피부 미백 화장료 조성물 |
KR101698163B1 (ko) * | 2014-12-19 | 2017-01-19 | 동아에스티 주식회사 | 복령피 추출물을 함유하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물 |
KR101671437B1 (ko) * | 2014-12-19 | 2016-11-01 | 동아에스티 주식회사 | 상심자 및 복령피 혼합 추출물을 함유하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물 |
CN104688782B (zh) * | 2015-02-05 | 2018-05-04 | 广东药科大学 | 一种从茯苓皮中高效提取三萜类活性成分的方法 |
CN105147592B (zh) * | 2015-10-16 | 2018-11-13 | 湖北穆兰同大科技有限公司 | 一种含有白茯苓的面膜及其制备方法 |
CN105639617A (zh) * | 2015-12-31 | 2016-06-08 | 湖南诺泽生物科技有限公司 | 一种茯苓的综合开发和应用的方法及其新用途 |
-
2017
- 2017-09-05 MY MYPI2019001172A patent/MY195806A/en unknown
- 2017-09-05 KR KR1020197009564A patent/KR102295786B1/ko active IP Right Grant
- 2017-09-05 WO PCT/CN2017/100526 patent/WO2018045943A1/zh active Application Filing
- 2017-09-05 CN CN201710789742.0A patent/CN107789373A/zh active Pending
- 2017-09-05 TW TW106130209A patent/TWI640317B/zh active
- 2017-09-05 JP JP2019533271A patent/JP6798030B2/ja active Active
- 2017-09-05 US US15/695,527 patent/US11654169B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08119864A (ja) * | 1994-09-02 | 1996-05-14 | Kotarou Kanpo Seiyaku Kk | 鎮吐薬 |
JPH0925232A (ja) * | 1995-07-14 | 1997-01-28 | Kotarou Kanpo Seiyaku Kk | 発癌予防剤 |
JPH0940552A (ja) * | 1995-08-02 | 1997-02-10 | Kanebo Ltd | ヒトコラゲナーゼ活性阻害剤 |
JPH10237093A (ja) * | 1997-02-28 | 1998-09-08 | Kotarou Kanpo Seiyaku Kk | マツホド抽出成分を含む抗炎症剤 |
JPH10330266A (ja) * | 1997-06-02 | 1998-12-15 | Kotarou Kanpo Seiyaku Kk | インスリン作用増強活性組成物 |
JP2003104905A (ja) * | 2001-09-28 | 2003-04-09 | Nagatomo Yakuhin:Kk | 茸有効成分の抽出方法 |
JP2008105972A (ja) * | 2006-10-24 | 2008-05-08 | Nagatomo Yakuhin:Kk | 生薬の抗腫瘍性有効物質の抽出法 |
US8168197B2 (en) * | 2007-02-28 | 2012-05-01 | Amorepacific Corporation | External composition for skin containing Scrophularia buergeriana miq. extract and the use thereof for the skin moisturizing cosmetics |
JP2011256136A (ja) * | 2010-06-09 | 2011-12-22 | Nihon Univ | コラーゲン分解阻害剤 |
CN103550265A (zh) * | 2013-11-08 | 2014-02-05 | 山东省中医药研究院 | 一种茯苓皮有效成分的提取方法及其提取物 |
KR20160003910A (ko) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | 한약재 추출물을 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물 |
Also Published As
Publication number | Publication date |
---|---|
WO2018045943A1 (zh) | 2018-03-15 |
MY195806A (en) | 2023-02-22 |
JP6798030B2 (ja) | 2020-12-09 |
TW201811350A (zh) | 2018-04-01 |
US11654169B2 (en) | 2023-05-23 |
KR102295786B1 (ko) | 2021-09-01 |
TWI640317B (zh) | 2018-11-11 |
KR20190064580A (ko) | 2019-06-10 |
CN107789373A (zh) | 2018-03-13 |
US20180064771A1 (en) | 2018-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6798030B2 (ja) | 皮膚ケアおよび/または創傷治癒促進における松塊抽出物およびその有効成分の使用 | |
JP2019529533A5 (ja) | ||
KR20150116659A (ko) | 천심련추출물 또는 안드로그라폴라이드 또는 이의 염을 포함하는 피부상태 개선용 조성물 | |
KR101809379B1 (ko) | 디오스민 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 | |
EP2229165A1 (en) | Anti-glycation properties of asicatic acid and madecassic acid | |
KR20230120619A (ko) | 피부 상태 개선용 조성물 | |
KR102033073B1 (ko) | 세리신, 사상자 추출물 및 겨우살이 추출물을 포함하는, 피부 재생, 진정 또는 상처 치유용 조성물 | |
JP2021521264A (ja) | 脱毛治療及び発毛促進用組成物 | |
KR101904501B1 (ko) | 퓨코스테롤을 유효성분으로 포함하는 피부주름 개선 또는 피부탄력 증진용 화장료 조성물 | |
JP2016130230A (ja) | 皮膚バリア機能改善剤、細胞間接着構造の形成促進剤、タイトジャンクション形成促進剤、TRPV4活性化剤、細胞内Ca濃度上昇亢進剤及び皮脂産生促進剤 | |
JP2019052113A (ja) | ヒアルロン酸産生促進剤及びヒアルロン酸産生促進用食品 | |
WO2008009655B1 (de) | Medizinische verwendung von n-phenylpropenoyl-aminosäurederivaten und verwandten verbindungen | |
KR102124065B1 (ko) | 식물 추출물을 함유하는 피부 주름 개선용 조성물 | |
KR101830395B1 (ko) | 스쿠알렌을 함유하는 근기능 향상 및 근육 손상 예방용 조성물 | |
JP7475873B2 (ja) | ディフェンシン発現促進剤 | |
JP2020182415A (ja) | 真皮幹細胞の分化促進剤 | |
US20230000758A1 (en) | Method for preventing skin aging comprising korean mint extract | |
JP2019052114A (ja) | コラーゲン産生促進剤及びコラーゲン産生促進用食品 | |
TWI701035B (zh) | 茯苓萃取物及土莫酸於保護肌肉之用途 | |
JP2006137680A (ja) | コラーゲン産生促進剤 | |
JP2017066051A (ja) | 終末糖化産物生成抑制剤 | |
TW202333756A (zh) | 胎盤組成物 | |
KR101177280B1 (ko) | 소목, 희첨 및 세포침투성 hsp27 융합단백질을 포함하는 항염증 피부외용제 조성물 | |
KR20230066692A (ko) | 흑생강(Kaempferia parviflora) 추출물 또는 이로부터 분리된 화합물을 포함하는 주름개선 기능성 조성물 | |
KR20210032145A (ko) | 바닐라빈 추출물을 포함하는 피부 재생용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190606 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20190504 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190504 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190723 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200401 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20200701 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201028 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6798030 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |